68449-30-9

Usage

Synthesis Reference(s)

The Journal of Organic Chemistry, 49, p. 4226, 1984 DOI: 10.1021/jo00196a024

InChI:InChI=1/C10H9BrO/c11-9-5-1-4-8-7(9)3-2-6-10(8)12/h1,4-5H,2-3,6H2

Upstream product

• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 

Downstream Products

• 87779-57-5 bromo-5 dihydro-3,4 naphthalene 
• 92013-31-5 5-bromotetralol 
• 138764-20-2 5-oxo-5,6,7,8-tetrahydronaphthalene-1-carbonitrile 
• 62784-49-0 5-bromo-1,2-naphthaquinone 
• 911836-37-8 5-bromo-1-phenyl-1,2,3,4-tetrahydro-naphthalen-1-ol 
• 910330-25-5 5-(m-methoxyphenyl)-1-tetralone 
• 910330-26-6 5-(m-chlorophenyl)-1-tetralone 
• 910330-24-4 5-(3-(trifluoromethyl)phenyl)-3,4-dihydronaphthalen-1(2H)-one 
• 90401-62-0 5-phenyl-1-tetralone 
• 97903-08-7 ethyl 5-<2-(tosyloxy)ethyl>-5,6,7,8-tetrahydronaphthalene-1-carboxylate 
• 42775-75-7 5-ethyltetralin 
• 66325-42-6 5-n-butyltetralin 
• 346690-13-9 4-bromo-benzo[a]phenazine-11-carboxylic acid 
• 1376129-11-1 N-(5-bromo-3,4-dihydronaphthalen-1-yl)benzamide 

Relevant academic research and scientific papers

Synthesis of multisubstituted cycloalkenes through carbomagnesiation of strained cycloalkynes

An efficient synthetic method of seven- and six-membered cycloalkenes through the generation of strained cycloalkynes and following carbomagnesiation is described. Further bond formations of the resulting cycloalkenylmagnesium intermediates with a wide variety of electrophiles enabled us to prepare diverse cycloalkene derivatives including benzoxepine analogs having a fully substituted alkene structure.

Revisiting secondary interactions in neighboring group participation, exemplified by reactivity changes of iminylium intermediates

Neighboring group participation is defined as the action of a substituent to stabilize a transition state or an intermediate by forming a bond or a partial bond with the reaction center. In addition to the primary interaction with the nearest neighboring group, secondary interactions involving another neighboring group(s) could also occur in principle. Here, we revisit this issue by examining the influence of secondary interactions on the stability and reactivity of the putative iminylium cation intermediates, formed by N-O bond cleavage of 1-tetralone oxime systems. A direct observation of a peri-bromo-iminylium intermediate in solution supported the involvement of iminylium cations and the stabilizing effect of secondary interactions arising from a distal tandem substituent. Both experimental and computational findings support the idea that secondary interactions of a tandem-neighboring group on the primary peri-heteroatom (Br, Cl, and O(Me))-iminylium bonding interaction, i.e., a weak halogen bonding interaction (ester (nitro) oxygen-halogen bonding) and an unprecedented hydrogen bonding interaction between a nitro oxygen atom and a CH3O hydrogen atom, are crucial determinants of the reaction pathway, leading to either overwhelmingly selective syn-migration of the oxime functionality or covalent bond formation under acid-catalyzed Beckmann rearrangement conditions.

Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease

A series of compounds bearing tetrahydronaphthalene, benzophenone, propiophenone, and related rigid molecular skeletons functionalized with thiosemicarbazone or unsaturated carbonyl moieties were prepared by chemical synthesis and evaluated for their ability to inhibit the enzyme cruzain. As potential treatment agents for Chagas' disease, three compounds from the group demonstrate potent inhibition of cruzain with IC50 values of 17, 24, and 80 nM, respectively.

METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS

The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES

Disclosed are compounds of the formula: where variables Q, Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal.

5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa

Syntheses and SAR studies of 5-amidinobenzo[b]thiophene analogs provided compounds with low submicromolar factor IXa potency and equal or slightly better selectivity relative to factor Xa. Syntheses and SAR studies of 5-amidinobenzo[b]thiophene analogs provided compounds with low submicromolar factor IXa activity and equal or slightly better selectivity relative to factor Xa.

BENZAMIDE 2-HYDROXY-3-DIAMINOALKANES

The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are also useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.

PHENACYL 2-HYDROXY-3-DIAMINOALKANES

The present invention relates to compounds of formula (I): useful in treating Alzheimer’s disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer’s disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are also useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation.

Indole derivatives for the treatment of depression and anxiety

The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.

Benzofuran derivatives

The present invention provides compounds of formula (I) which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine.